Checked.be
Active
BE 0821.390.951Private limited company
APOTHEEK BROEKAERT
Zwijnaardsesteenweg 266 ·9000 Gent, Belgium· 16 yrs active
Sector: Retail sale of pharmaceutical products
(47730)
Conclusion
APOTHEEK BROEKAERT has been active since 2009 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €389k and a net result of €19k. Equity is growing by ~6.5% per year across the filed fiscal years. Its solvency ranks better than 89% of 26065 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.7% (low).
Based on the State Gazette, CBE and 3 annual accounts.
Key figures
| Equity | €389k |
| Net result | €19k |
| Better than sector | 89% |
| Active | 16 yrs |
Financial profile
73
/ 100
Strong profile, led by solvency.
All 5 axes are computed from data Checked has read.
Health
86
Profitability
25
Solvency
100
Growth
52
Stability
100
Bankruptcy probability (12 mo)
Risk Assessment
0 / 100
Low riskTrust signals
Established
Founded in 2009, 16 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Checked score
86
/ 100
Excellent
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
Indicative credit limit
€35k
estimate, not credit advice
Score history
93
2022
86
2023
86
2024
purely financial, excl. current insolvency signals
Score components
Liquidity
Current ratio 5.44 (≥ 1.5)
+10
Quick ratio
Quick ratio 4.90 (≥ 1.0)
+5
Leverage
Debt/equity 0.23 (< 1.0)
+10
Profitability
ROE 5%
+3
Interest coverage
Interest coverage 6.6× (≥ 3×)
+8
Profit trend
Net profit down YoY
-3
Equity growth
Equity growing YoY
+3
Computed by Checked from the NBB filing for FY 2024. Indicative, not credit advice.
Financial overview
Annual accounts filed on 08-10-2025 with the NBB · fiscal year 2024 · micro schema
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
growing
Equity: growth of ~6.5%/year over 3 fiscal years, indicative, assuming unchanged policy.
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Sector comparison
Fiscal year 2024 · NACE 47, Retail trade · compared within the same schema type (micro schema)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 81.3% | 32.3% | |
| Net result | €19k | €4k | |
| Equity | €389k | €39k | |
| Gross operating margin | €36k | €31k | |
| Total assets | €479k | €146k |
€34k
-30.9%
22-24
€19k
-33.4%
22-24
€23k
-35.6%
22-24
€479k
+3.2%
22-24
€389k
+5.2%
22-24
€384k
+6.5%
22-24
€8k
-30.0%
22-24
€90k
-4.8%
22-24
€86k
-6.0%
22-24
5.44
+10.7%
22-24
4.90
+10.9%
22-24
81.3%
+2.0%
22-24
0.23
-9.5%
22-24
4.9%
-36.7%
22-24
4.0%
-35.5%
22-24
6.59
-51.9%
22-24
Figures by fiscal year and ratios
| Fiscal year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Deposit | micro schema | micro schema | micro schema |
| Revenue | - | - | - |
| EBITDA | €34k | €49k | €70k |
| Net profit | €19k | €29k | €45k |
| Cash flow | €23k | €35k | €51k |
| Staff costs | - | - | - |
| Income taxes | €8k | €11k | €18k |
| Dividends | - | - | - |
| Total assets | €479k | €464k | €462k |
| Equity | €389k | €370k | €341k |
| Debt | €90k | €94k | €121k |
| of which ≤ 1y | €86k | €92k | €119k |
| of which > 1y | - | - | - |
| Working capital | €384k | €360k | €329k |
| Employees (FTE) | - | - | - |
Ratios (computed)
| 2024 | 2023 | 2022 | |
|---|---|---|---|
| Current ratio | 5.44 | 4.92 | 3.76 |
| Quick ratio | 4.90 | 4.42 | 3.41 |
| Working capital ratio | 80.2% | 77.7% | 71.3% |
| Solvency | 81.3% | 79.7% | 73.8% |
| Debt / equity | 0.23 | 0.25 | 0.35 |
| Long-term debt ratio | - | - | - |
| Interest coverage | 6.59 | 13.70 | 28.47 |
| Gross margin | - | - | - |
| Net margin | - | - | - |
| ROA | 4.0% | 6.2% | 9.7% |
| ROE | 4.9% | 7.8% | 13.2% |
| EBITDA margin | - | - | - |
| Days sales outstanding | - | - | - |
| Days payable outstanding | - | - | - |
| Inventory turnover | - | - | - |
| Days inventory (DSI) | - | - | - |
Balance-sheet composition 2024
Full annual accounts (23 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Balance sheet, Assets | ||||
| TOTAL ASSETS | 20/58 | €479k | €464k | €462k |
| Fixed assets | 21/28 | €8k | €12k | €13k |
| Tangible fixed assets | 22/27 | €8k | €12k | €13k |
| Current assets | 29/58 | €471k | €452k | €449k |
| Stocks & contracts in progress | 3 | €47k | €46k | €42k |
| Amounts receivable within one year | 40/41 | €58k | €39k | €42k |
| Investments | 50/53 | €1k | €1k | €1k |
| Cash & bank | 54/58 | €364k | €364k | €362k |
| Balance sheet, Equity & liabilities | ||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €479k | €464k | €462k |
| Equity | 10/15 | €389k | €370k | €341k |
| Contributions / capital | 10/11 | €50k | €50k | €50k |
| Reserves | 13 | €339k | €320k | €291k |
| Amounts payable | 17/49 | €90k | €94k | €121k |
| Amounts payable within one year | 42/48 | €86k | €92k | €119k |
| Trade debts payable within one year | 44 | €25k | €30k | €53k |
| Income statement | ||||
| Gross operating margin | 9900 | €36k | €51k | €72k |
| Operating result | 9901 | €30k | €42k | €65k |
| Financial income | 75 | €2k | €1k | €557 |
| Financial charges | 65 | €5k | €4k | €2k |
| Result before taxes | 9903 | €27k | €40k | €63k |
| Income taxes | 67/77 | €8k | €11k | €18k |
| Net result for the period | 9904 | €19k | €29k | €45k |
| Result to be appropriated | 9905 | €19k | €29k | €45k |
Legal Structure
| NACE primary | Retail sale of pharmaceutical products(47730) |
| Legal form | Private limited company(610) |
| Incorporation | 11-12-2009 |
| Status | Active |
| Postal code | 9000 |
Establishment units
APOTHEEK BROEKAERT
since 20092.183.787.625
Real-estate footprint
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 44808H0132/00S000 | Flanders | 134 m² | 1 · 114 m² | 14.8 m · 5 fl. |
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates
2025
08-10
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 69 days late
2024
31-12
Financial
Weakest financial yearnet €19k ▼33.4%
Net result drops to €19k, the lowest in the series.
30-08
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 30 days late
2023
31-08
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema · 31 days late
2022
31-08
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema · 31 days late
2021
31-08
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema · 31 days late
2020
09-11
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema · 101 days late
2019
30-08
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema · 30 days late
2018
17-08
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema · 17 days late
2017
30-08
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema · 30 days late
2016
29-08
NBB filing
Annual accounts filed
fiscal year 2015 · abbreviated schema · 29 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Belgian State Gazette reading coverage
We know of 2 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Credit advice
Company registry (CBE)
Activities
Retail sale of pharmaceutical products47730
Names & trade names
| Legal nameNL | APOTHEEK BROEKAERT |
Similar companies
Apotheek Bambrugge
BE 0661.688.963 · Erpe-Mere
APPROVER
BE 0872.752.055 · Lier
APOTHEEK RYCKAERT-VERSCHOOTE
BE 0426.679.937 · Sint-Laureins
APOTHEEK DE STATIE
BE 0872.274.775 · Nijlen
Gooreind Pharma
BE 0870.403.170 · Wuustwezel